1. Scrip
  2. >>Therapy Areas

TG and Rhizen to co-develop PI3K inhibitor

 
• By Mandy Jackson

New York-based TG Therapeutics has licensed a phosphoinositide-3-kinase (PI3K) inhibitor of the delta pathway from Rhizen Pharmaceuticals of Switzerland that it hopes to position as one of the first PI3K therapies on the market for haematological malignancies and autoimmune disorders.

New York-based TG Therapeutics has licensed a phosphoinositide-3-kinase (PI3K) inhibitor of the delta pathway from Rhizen Pharmaceuticals of Switzerland that it hopes to position as one of the first PI3K therapies on the market for haematological malignancies and autoimmune disorders.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapeutic Category

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 
• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By Xu Hu

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.